Search

Your search keyword '"Tjin Tham Sjin, Robert"' showing total 20 results
Start Over Author "Tjin Tham Sjin, Robert"
20 results on '"Tjin Tham Sjin, Robert"'

1. Supplementary Tables 1 through 4 and Supplementary Figures 1 through 5 from In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Author

Tjin Tham Sjin, Robert, primary, Lee, Kwangho, primary, Walter, Annette O., primary, Dubrovskiy, Aleksandr, primary, Sheets, Michael, primary, Martin, Thia St., primary, Labenski, Matthew T., primary, Zhu, Zhendong, primary, Tester, Richland, primary, Karp, Russell, primary, Medikonda, Aravind, primary, Chaturvedi, Prasoon, primary, Ren, Yixuan, primary, Haringsma, Henry, primary, Etter, Jeff, primary, Raponi, Mitch, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Westlin, William F., primary, Petter, Russell C., primary, Allen, Andrew, primary, and Singh, Juswinder, primary

Published
2023
Full Text
View/download PDF

2. Supplementary Materials and Methods and Supplementary Figure Legends from In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Author

Tjin Tham Sjin, Robert, primary, Lee, Kwangho, primary, Walter, Annette O., primary, Dubrovskiy, Aleksandr, primary, Sheets, Michael, primary, Martin, Thia St., primary, Labenski, Matthew T., primary, Zhu, Zhendong, primary, Tester, Richland, primary, Karp, Russell, primary, Medikonda, Aravind, primary, Chaturvedi, Prasoon, primary, Ren, Yixuan, primary, Haringsma, Henry, primary, Etter, Jeff, primary, Raponi, Mitch, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Westlin, William F., primary, Petter, Russell C., primary, Allen, Andrew, primary, and Singh, Juswinder, primary

Published
2023
Full Text
View/download PDF

3. Supplementary Data from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma

Author

Shields, Julie A., primary, Meier, Samuel R., primary, Bandi, Madhavi, primary, Mulkearns-Hubert, Erin E., primary, Hajdari, Nicole, primary, Ferdinez, Maria Dam, primary, Engel, Justin L., primary, Silver, Daniel J., primary, Shen, Binzhang, primary, Zhang, Wenhai, primary, Hubert, Christopher G., primary, Mitchell, Kelly, primary, Shakya, Sajina, primary, Zhao, Shan-Chuan, primary, Bejnood, Alborz, primary, Zhang, Minjie, primary, Tjin Tham Sjin, Robert, primary, Wilker, Erik, primary, Lathia, Justin D., primary, Andersen, Jannik N., primary, Chen, Yingnan, primary, Li, Fang, primary, Weber, Barbara, primary, Huang, Alan, primary, and Emmanuel, Natasha, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma

Author

Shields, Julie A., primary, Meier, Samuel R., primary, Bandi, Madhavi, primary, Mulkearns-Hubert, Erin E., primary, Hajdari, Nicole, primary, Ferdinez, Maria Dam, primary, Engel, Justin L., primary, Silver, Daniel J., primary, Shen, Binzhang, primary, Zhang, Wenhai, primary, Hubert, Christopher G., primary, Mitchell, Kelly, primary, Shakya, Sajina, primary, Zhao, Shan-Chuan, primary, Bejnood, Alborz, primary, Zhang, Minjie, primary, Tjin Tham Sjin, Robert, primary, Wilker, Erik, primary, Lathia, Justin D., primary, Andersen, Jannik N., primary, Chen, Yingnan, primary, Li, Fang, primary, Weber, Barbara, primary, Huang, Alan, primary, and Emmanuel, Natasha, primary

Published
2023
Full Text
View/download PDF

5. Data from VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma

Author

Shields, Julie A., primary, Meier, Samuel R., primary, Bandi, Madhavi, primary, Mulkearns-Hubert, Erin E., primary, Hajdari, Nicole, primary, Ferdinez, Maria Dam, primary, Engel, Justin L., primary, Silver, Daniel J., primary, Shen, Binzhang, primary, Zhang, Wenhai, primary, Hubert, Christopher G., primary, Mitchell, Kelly, primary, Shakya, Sajina, primary, Zhao, Shan-Chuan, primary, Bejnood, Alborz, primary, Zhang, Minjie, primary, Tjin Tham Sjin, Robert, primary, Wilker, Erik, primary, Lathia, Justin D., primary, Andersen, Jannik N., primary, Chen, Yingnan, primary, Li, Fang, primary, Weber, Barbara, primary, Huang, Alan, primary, and Emmanuel, Natasha, primary

Published
2023
Full Text
View/download PDF

6. VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma

Author

Shields, Julie A., primary, Meier, Samuel R., additional, Bandi, Madhavi, additional, Mulkearns-Hubert, Erin E., additional, Hajdari, Nicole, additional, Ferdinez, Maria Dam, additional, Engel, Justin L., additional, Silver, Daniel J., additional, Shen, Binzhang, additional, Zhang, Wenhai, additional, Hubert, Christopher G., additional, Mitchell, Kelly, additional, Shakya, Sajina, additional, Zhao, Shan-Chuan, additional, Bejnood, Alborz, additional, Zhang, Minjie, additional, Tjin Tham Sjin, Robert, additional, Wilker, Erik, additional, Lathia, Justin D., additional, Andersen, Jannik N., additional, Chen, Yingnan, additional, Li, Fang, additional, Weber, Barbara, additional, Huang, Alan, additional, and Emmanuel, Natasha, additional

Published
2022
Full Text
View/download PDF

9. This title is unavailable for guests, please login to see more information.

Author

CMM Sectie Molecular Cancer Research, Galvani, Elena, Sun, Jing, Leon, Leticia G, Sciarrillo, Rocco, Narayan, Ravi S, Tjin Tham Sjin, Robert, Lee, Kwangho, Ohashi, Kadoaki, Heideman, Daniëlle A M, Alfieri, Roberta R, Heynen, Guus J, Bernards, René, Smit, Egbert F, Pao, William, Peters, Godefridus J, Giovannetti, Elisa, CMM Sectie Molecular Cancer Research, Galvani, Elena, Sun, Jing, Leon, Leticia G, Sciarrillo, Rocco, Narayan, Ravi S, Tjin Tham Sjin, Robert, Lee, Kwangho, Ohashi, Kadoaki, Heideman, Daniëlle A M, Alfieri, Roberta R, Heynen, Guus J, Bernards, René, Smit, Egbert F, Pao, William, Peters, Godefridus J, and Giovannetti, Elisa

Published
2015

10. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

Author

Galvani, Elena, Sun, Jing, Leon, Leticia G, Sciarrillo, Rocco, Narayan, Ravi S, Tjin Tham Sjin, Robert, Lee, Kwangho, Ohashi, Kadoaki, Heideman, Daniëlle A M, Alfieri, Roberta R, Heynen, Guus J, Bernards, René, Smit, Egbert F, Pao, William, Peters, Godefridus J, Giovannetti, Elisa, Galvani, Elena, Sun, Jing, Leon, Leticia G, Sciarrillo, Rocco, Narayan, Ravi S, Tjin Tham Sjin, Robert, Lee, Kwangho, Ohashi, Kadoaki, Heideman, Daniëlle A M, Alfieri, Roberta R, Heynen, Guus J, Bernards, René, Smit, Egbert F, Pao, William, Peters, Godefridus J, and Giovannetti, Elisa

Published
2015

11. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

Author

Galvani, Elena, primary, Sun, Jing, additional, Leon, Leticia G., additional, Sciarrillo, Rocco, additional, Narayan, Ravi S., additional, Tjin Tham Sjin, Robert, additional, Lee, Kwangho, additional, Ohashi, Kadoaki, additional, Heideman, Daniëlle A.M., additional, Alfieri, Roberta R., additional, Heynen, Guus J., additional, Bernards, René, additional, Smit, Egbert F., additional, Pao, William, additional, Peters, Godefridus J., additional, and Giovannetti, Elisa, additional

Published
2015
Full Text
View/download PDF

12. In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Author

Tjin Tham Sjin, Robert, primary, Lee, Kwangho, additional, Walter, Annette O., additional, Dubrovskiy, Aleksandr, additional, Sheets, Michael, additional, Martin, Thia St., additional, Labenski, Matthew T., additional, Zhu, Zhendong, additional, Tester, Richland, additional, Karp, Russell, additional, Medikonda, Aravind, additional, Chaturvedi, Prasoon, additional, Ren, Yixuan, additional, Haringsma, Henry, additional, Etter, Jeff, additional, Raponi, Mitch, additional, Simmons, Andrew D., additional, Harding, Thomas C., additional, Niu, Deqiang, additional, Nacht, Mariana, additional, Westlin, William F., additional, Petter, Russell C., additional, Allen, Andrew, additional, and Singh, Juswinder, additional

Published
2014
Full Text
View/download PDF

15. Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

Author

Singh, Juswinder, primary, Evans, Erica, additional, Hagel, Margit, additional, Labinski, Matthew, additional, Dubrovskiy, Alex, additional, Nacht, Mariana, additional, Petter, Russell C., additional, Prasad, Aravind, additional, Sheets, Michael, additional, St Martin, Thia, additional, Tjin Tham Sjin, Robert, additional, Westlin, William, additional, and Zhu, Zhendong, additional

Published
2012
Full Text
View/download PDF

18. A novel IL-6 response element confers specificity for JunB induction in M1 myeloid versus HepG2 hepatoma cells

Author

Tjin Tham Sjin, Robert Mark and Tjin Tham Sjin, Robert Mark

Abstract

Interleukin-6 (IL-6) is a multifunctional cytokine which plays an important role in a wide range of biological activities, including differentiation of murine M1 myeloid leukemic cells into mature macrophages. At the onset of M1 differentiation, a set of myeloid differentiation primary response (MyD) genes are induced, including the proto-oncogene JunB. However, the molecular nature of the mechanisms by which IL-6 activates the immediate early expression of MyD genes has not been elucidated. Towards this end, we used JunB as a paradigm to examine the IL-6-mediated activation of MyD genes, by identifying and characterizing IL-6 responsive cis-regulatory elements of the JunB promoter and transacting factors that bind to them. It is shown that a novel IL-6 responsive element resides between sequences $-$65bp and $-$52bp upstream from the JunB transcription start site. This $-$65/-52 IL-6 response element (IL-6RE), which contains a CCAAT box motif, is shown to be necessary and sufficient for the IL-6 response. The STAT3 and CRE-like binding sites of the JunB promoter, identified as IL-6 responsiveness elements in HepG2 liver cells, play no role in JunB inducibility by IL-6 in M1 myeloid cells. Conversely, the $-$65/$-$52 IL-6RE is shown not to be necessary for JunB inducibility by IL-6 in liver cells. Thus, immediate early activation of JunB via the $-$65/$-$52 IL-6RE appears to be myeloid specific. Analysis of nuclear proteins that bind to the $-$65/$-$52 IL-6RE revealed that NF-Y was a component of the protein complex bound to the $-$65/$-$52 IL-6RE. This is the first incident where NF-Y has been identified as a target for IL-6 signaling. In addition, the promoter regions of other MyD genes were found to contain NF-Y binding sites, suggesting that NF-Y plays a role in the mechanisms that lead to the coordinate induction by IL-6 of immediate early MyD genes following induction of myeloid differentiation.

Published
1998

19. Perivascular endothelial ceils increase positive remodeling by down regulation of matrix metalloproteinase (MMP)-2 in porcine arteriovenous grafts.

Author

Nugent, Helen, Tjin Tham Sjin, Robert, White, Desmond, Milton, Luther, Manson, Roberto, Lawson, Jeffrey, and Edelman, Elazer

Subjects
*EPITHELIAL cells, *METALLOPROTEINASES, *NERVE grafting, *ARTIFICIAL implants, *STENOSIS
Abstract

Vascular access dysfunction is a major problem in hemodialysis patients. Arteriovenous (AV) grafts have a patency rate of only 50% at 1 year. Vein maturation is an important factor in the success of an AV graft, the vein must remodel to accommodate arterial blood flow and pressure. We examined the role of perivascular endothelial implants in venous remodeling and stenosis. The data presented here provides insight into the mechanism of the implants and AV graft failure. End-to-side carotid artery-jugular vein AV grafts were created in swine and the anastomoses wrapped with Gelfoam® matrices containing porcine endothelial cells (PAE, n = 10) or control matrices without cells (n = 10). The biological response was investigated at 3 days and 1-month post-operatively. PAE implants significantly increased venous lumen gain. The treated veins increased in diameter from 1.04 ± 0.09 at day 0 to 2.9 ± 0.56 at 1-month, P<0.05, while control veins remained unchanged from 1.28 ± 0.13 at day 0 to 1.29 ± 0.35 at 1-month (Fig. 1). The implants also reduced the percent stenosis by 81%, P<0.05. These data correlated with a significant reduction in MMP-2 expression (Fig. 2), adventitial fibrosis and neovascularization in treated veins compared to control, P<0.05. This study suggests that PAE implants significantly increased venous lumen diameter and reduced stenosis at 1-month in porcine AV grafts. Funding provided by Pervasis Therapeutics. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

20. Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles.

Author

Javaherian K, Lee TY, Tjin Tham Sjin RM, Parris GE, and Hlatky L

Abstract

Angiogenesis refers to growth of blood vessels from pre-existing ones. In 1971, Folkman proposed that by choking off the blood supply to tumors, they are starved, leading to their demise. A few years ago, the monoclonal antibody Avastin became the first antiangiogenic biological approved by FDA, for treatment of cancer patients. Two other antiangiogenic endogenous protein fragments were isolated in Folkman's laboratory more than a decade ago. Here, we present a short review of data demonstrating that angiostatin and endostatin display a biphasic antitumor dose-response. This behavior is common among a large number of antiangiogenic agents and the reduced effectiveness of antiangiogenic agents at high dose rates may be due to suppression of growth of new vessels carrying the agent into the critical region around the tumor.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results